Efficacy and safety of torsemide versus furosemide in heart failure patients: A systematic review of randomized controlled trials

To the Editor, Heart failure (HF) is a leading cause of morbidity and mortality globally. 1 Loop diuretics, such as torsemide and furosemide, are routinely used for managing fluid overload in patients with HF. 2 Although furosemide is the most widely used loop diuretic, some studies and prior meta-a...

Full description

Saved in:
Bibliographic Details
Published inClinical cardiology (Mahwah, N.J.) Vol. 47; no. 1; pp. e24088 - n/a
Main Authors Ahmad Cheema, Huzaifa, Azeem, Saleha, Ejaz, Abdullah, Khan, Faiza, Muhammad, Anza, Shahid, Abia, Nashwan, Abdulqadir J., Maqsood, Muhammad Haisum, Dani, Sourbha S., Mentz, Robert J., Fudim, Marat, Fonarow, Gregg C.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.01.2024
John Wiley and Sons Inc
Subjects
Bias
Conflicts of interest
Correspondence
Diuretics
Ejection fraction
Heart failure
Hospitalization
Mortality
Patients
Systematic review
Online AccessGet full text

Cover

More Information
Summary:To the Editor, Heart failure (HF) is a leading cause of morbidity and mortality globally. 1 Loop diuretics, such as torsemide and furosemide, are routinely used for managing fluid overload in patients with HF. 2 Although furosemide is the most widely used loop diuretic, some studies and prior meta-analyses suggested that torsemide may be superior to furosemide with fewer adverse effects while achieving similar or better outcomes including potential survival benefit. 3,4 However, current evidence remains inconsistent and previous reviews may have been biased due to the inclusion of observational studies. 3 In addition, the results of the TRANSFORM-HF trial by Mentz et al., the largest randomized controlled trial (RCT) on this topic to date involving 2859 patients, have recently been published. 5 Hence, we conducted an updated systematic review of RCTs to provide more conclusive evidence regarding the efficacy and safety of torsemide versus furosemide in HF patients. Due to the heterogeneous nature of included trials in terms of study design, sample size, patient population, and intervention characteristics, we did not conduct a meta-analysis. [...]torsemide and furosemide are comparable regarding all-cause and cardiac mortality, hospitalization, and adverse events in patients with HF.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.24088